160 related articles for article (PubMed ID: 9693964)
21. [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam (3)--Perinatal and postnatal study in rats with intraperitoneal administration].
Sato T; Hoberman AM; Christian MS
J Toxicol Sci; 1994 Oct; 19 Suppl 2():233-47. PubMed ID: 7830289
[TBL] [Abstract][Full Text] [Related]
22. [A six-month intraperitoneal repeated dose toxicity study of tazobactam/piperacillin and tazobactam in rats].
Hayashi T; Yada H; Auletta CS; Daly IW; Knezevich AL; Cockrell BY
J Toxicol Sci; 1994 Oct; 19 Suppl 2():155-76. PubMed ID: 7830285
[TBL] [Abstract][Full Text] [Related]
23. Onset of Hemophagocytic Lymphohistiocytosis during Piperacillin-Tazobactam Therapy in Three Children with Acute Focal Bacterial Nephritis.
Miyabayashi H; Kumaki S; Sato A; Onuma R; Noguchi R; Sato T; Metoki T; Watanabe Y; Tazawa Y; Imaizumi M; Kitaoka S
Tohoku J Exp Med; 2018 May; 245(1):55-59. PubMed ID: 29798969
[TBL] [Abstract][Full Text] [Related]
24. Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day.
Kobayashi R; Sano H; Matsushima S; Hori D; Yanagi M; Kodama K; Suzuki D; Kobayashi K
Int J Hematol; 2021 Mar; 113(3):430-435. PubMed ID: 33170417
[TBL] [Abstract][Full Text] [Related]
25. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
[TBL] [Abstract][Full Text] [Related]
26. [Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin].
Hidai H
Nihon Rinsho; 2001 Apr; 59(4):785-9. PubMed ID: 11305007
[TBL] [Abstract][Full Text] [Related]
27. [Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam(1)--Fertility and general reproduction study in rats with intraperitoneal administration].
Sato T; Lochry EA; Hoberman AM; Christian MS
J Toxicol Sci; 1994 Oct; 19 Suppl 2():199-24. PubMed ID: 7830287
[TBL] [Abstract][Full Text] [Related]
28. [A six-month intravenous repeated dose toxicity study of tazobactam/piperacillin and tazobactam in dogs].
Hayashi T; Yada H; Blair M; Laughlin KA; Blanchard GL; Tucek PC; Geil RG
J Toxicol Sci; 1994 Oct; 19 Suppl 2():177-97. PubMed ID: 7830286
[TBL] [Abstract][Full Text] [Related]
29. [Single-dose toxicity studies of tazobactam/piperacillin and tazobactam].
Hayashi T; Yada H; Anai M; Umano T; Kawazu K; Anai S; Kaziwara T; Yamasaki K
J Toxicol Sci; 1994 Oct; 19 Suppl 2():145-53. PubMed ID: 7830284
[TBL] [Abstract][Full Text] [Related]
30. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients.
Kobayashi R; Sato T; Nakajima M; Kaneda M; Iguchi A
J Pediatr Hematol Oncol; 2009 Apr; 31(4):270-3. PubMed ID: 19346879
[TBL] [Abstract][Full Text] [Related]
31. Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).
Higashitani F; Nishida K; Hyodo A; Inoue M
J Antibiot (Tokyo); 1995 Sep; 48(9):1027-33. PubMed ID: 7592048
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
[TBL] [Abstract][Full Text] [Related]
33. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
[TBL] [Abstract][Full Text] [Related]
34. Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Wang F; Schwenk MH
Ann Pharmacother; 1995 Oct; 29(10):1051-2. PubMed ID: 8845552
[No Abstract] [Full Text] [Related]
35. [Antigenicity tests of tazobactam/piperacillin, tazobactam and piperacillin].
Takemoto M; Matsuo K; Oguro M; Kouchi Y
J Toxicol Sci; 1994 Oct; 19 Suppl 2():249-62. PubMed ID: 7830290
[TBL] [Abstract][Full Text] [Related]
36. [Mutagenicity tests of tazobactam/piperacillin, tazobactam and piperacillin].
Ohuchida A; Taniguti A; Kouchi Y; Maeda Y; Kashihara A; Omae S
J Toxicol Sci; 1994 Oct; 19 Suppl 2():263-80. PubMed ID: 7830291
[TBL] [Abstract][Full Text] [Related]
37. [In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Feb; 55(1):61-6. PubMed ID: 11977921
[TBL] [Abstract][Full Text] [Related]
38. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
40. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
Sugimoto N; Yamagishi Y; Mikamo H
J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
